Masoprocol - Shaman Pharmaceuticals
Alternative Names: SP 134101Latest Information Update: 02 Oct 2021
At a glance
- Originator Shaman Pharmaceuticals
- Developer Merck Sante; Shaman Pharmaceuticals
- Class Anti-inflammatories; Catechols; Lignans; Small molecules
- Mechanism of Action Lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension; Type 2 diabetes mellitus
Most Recent Events
- 27 Jul 2000 Discontinued-Preclinical for Hypertension in USA (PO)
- 27 Jul 2000 Discontinued-Preclinical for Type-2 diabetes mellitus in USA (Unknown route)